CLINICAL RELEVANCE. D. A. Grosenbaugh, DVM, PhD a C. S. Backus, DVM, PhD b K. Karaca, DVM, PhD a J. M. Minke, DVM, PhD c R. M. Nordgren, DVM, PhD a
|
|
- Cuthbert Nichols
- 6 years ago
- Views:
Transcription
1 The Anamnestic Serologic Response to Vaccination with a Canarypox Virus Vectored Recombinant West Nile Virus (WNV) Vaccine in Horses Previously Vaccinated with an Inactivated WNV Vaccine* D. A. Grosenbaugh, DVM, PhD a C. S. Backus, DVM, PhD b K. Karaca, DVM, PhD a J. M. Minke, DVM, PhD c R. M. Nordgren, DVM, PhD a a Merial Limited 115 Transtech Drive Athens, GA c Merial SAS 254 rue Marcel Merieux Lyon, France b Countryside Veterinary Service 2922 Black Fox Trail Louisville, TN CLINICAL RELEVANCE A new recombinant West Nile virus (WNV) vaccine has been licensed for use in horses. Before this vaccine became available in 2004, the only equine WNV vaccine on the market had been an inactivated vaccine. Since the recombinant vaccine only expresses selected viral genes, the present study investigated whether a single dose of the recombinant vaccine is effective in producing an anamnestic serologic response in horses previously vaccinated with an inactivated WNV vaccine. Vaccination of horses with a canarypox-vectored recombinant vaccine, under field conditions, results in a marked anamnestic response in horses previously vaccinated with an inactivated WNV vaccine. INTRODUCTION A new recombinant West Nile virus (WNV) vaccine, expressing the premembrane (prm) and envelope (E) genes of WNV, has been licensed for use in horses. 1 This vaccine has been *Funding for this study was provided by Merial Limited, Duluth, Georgia. shown to provide a rapid onset of protection from viremia following challenge with WNVinfected mosquitoes after a single administration of vaccine. 2 Immunization with a canarypox virus recombinant vaccine results in the presentation of antigens in a manner analogous to that of the wild-type infection, in the ab- 251
2 Veterinary Therapeutics Vol. 5, No. 4, Winter 2004 TABLE 1. Age and Gender of Horses from Trial 1 (Blount County, Tennessee) and Trial 2 (Solano County, California) Location Vaccination Group Age (yr ± SE) Gender (M/G/S) Blount County, Tennessee Inactivated 4.4 ± 1.3 ( yr) 10/2/1 Blount County, Tennessee Recombinant 7.5 ± 2.2 ( yr) 8/4/2 Solano County, California Recombinant 4.0 ± 1.4 (1 16 yr) 6/4/1 G = gelding; M = mare; S = stallion. sence of productive viral replication. 3,4 This method of antigen presentation by recombinant canarypox virus vaccines has been shown to be capable of providing protection after the decline of detectable serum antibody levels, at a time during which antigen-specific T-cell responses can be elicited. 1,5 This authentic antigen presentation in the absence of viral infection removes the potential for transmission of the vaccine vector or the possibility of infectious disease resulting from incomplete inactivation of conventional vaccines, which has been implicated with respect to an inactivated Eastern equine encephalomyelitis virus vaccine. 6 Before the recombinant vaccine became available, the only equine WNV vaccine on the market had been an inactivated vaccine, which was introduced in 2001 in the face of a disease outbreak in the United States. Following a peak of reported equine WNV cases in 2002, the number of clinical cases in horses has declined, which has been attributed to effective vaccination programs, 7 although subclinical exposure is likely to have played a major role. Because all horses vaccinated for WNV before 2004 would have received the inactivated vaccine, we investigated whether a single dose of the recombinant vaccine, expressing the prm and E genes of the WNV, could induce an anamnestic serologic response in horses previously vaccinated with the killed vaccine. Horses from both a WNV-endemic region and a region for which WNV had not yet been reported were included in the study. MATERIALS AND METHODS Two trials were conducted independently. One was conducted in an area in which WNV disease in horses has been reported and the other in an area considered free from WNV at the time of the study. Horses Horses were identified from two regions of the United States: Blount County, Tennessee, where WNV is considered to be endemic, 8 and Solano County, California, where WNV infection in horses had not been reported at the time of the trial. 9 Each group of horses was housed on single premises under uniform management conditions. All horses were used under a protocol approved by Merial s Institutional Animal Care and Use Committee. In Trial 1, 27 horses ranging in age from 1.5 to 23 years were randomized into two groups with respect to date of last vaccination with an inactivated WNV vaccine. In Trial 2, 11 horses ranging in age from 1 to 16 years and likewise previously vaccinated with the inactivated vaccine but presumably unexposed to natural infection were included in the study. The age and gender of the two herds and their group assignment are listed in Table 1. Vaccines Recombitek Equine WNV vaccine (Merial) is an ALVAC (canarypox) based recom- 252
3 binant vaccine expressing the prm and E genes of a 1999 New York isolate of WNV. West Nile-Innovator (Fort Dodge Animal Health) is a killed, adjuvanted WNV vaccine. Vaccination Two trials were conducted in which all horses had been previously vaccinated with the inactivated WNV vaccine as per label recommendation. Trial 1 (Blount County, Tennessee) In Trial 1, the primary vaccination protocol (two doses) was completed between 18 and 25 weeks (24 ± 2 weeks; mean ± SD) before the initiation of the study in September of the We investigated whether a single dose of the recombinant vaccine could induce an anamnestic serologic response in horses previously vaccinated with the killed vaccine. same year. Horses received a single dose (1 ml IM) of either the inactivated WNV vaccine or the recombinant WNV vaccine. Trial 2 (Solano County, California) In Trial 2, horses in the WNV-free area had received either a single booster between 32 and 42 weeks before the start of the study (n = 8) or the three-dose protocol of the inactivated vaccine 21 weeks previously (n = 3). The mean duration to revaccination was 35 ± 9 weeks (mean ± SD). All horses received a single dose (1 ml IM) of the recombinant WNV vaccine in March of the following year. Serology Blood was collected from all horses before they were vaccinated and at 7 and 14 days postvaccination in Trial 1 or 16 and 29 days postvaccination in Trial 2. The serum was separated and maintained at 20 C until analysis for the presence of serum neutralization antibodies against WNV by the plaque reduction neutralization test (PRNT) at Colorado State University, Animal Disease Lab, Foothills Campus, Fort Collins, Colorado. Personnel doing the laboratory analysis were blind to group assignment. Briefly, sera were heat-inactivated at 56 C for 30 minutes and serial twofold dilutions of those sera were mixed with an equal volume (0.10 ml) containing 200 to 300 plaque-forming units of the NY strain of WNV. Following overnight incubation at 4 C, 0.1 ml of each mixture was applied to Vero cell monolayers in six-well plates. Neutralization endpoints were recorded as the highest dilution of serum resulting in a 90% reduction of 100 to 150 plaques. Titers greater than 10 were considered positive. Duplicate samples from the horses in the first trial were submitted to the National Veterinary Services Laboratories, Ames, Iowa, for determination of WNV-specific IgM response by IgM capture ELISA. For this assay, diluted serum samples were added to 96-well plates, coated with goat anti horse IgM antibody, and incubated overnight with either WNV tissue culture antigen or normal control tissue culture antigen. The optical density (OD) of each well was measured at 450 nm after incubation with a horseradish peroxidase-monoclonal WNV antibody conjugate, followed by tetramethylbenzidine substrate. The results were expressed as the difference between the absorbance of light at 450 nm (A450 nm) of the test sera on WNV antigen and test sera on normal control tissue culture antigen
4 Veterinary Therapeutics Vol. 5, No. 4, Winter 2004 TABLE 2. Distribution of Prevaccination Serum Antibody Titers Among Horses Vaccinated with the Recombinant or Inactivated Vaccine Titration End-Point Trial Booster Vaccine < >160 Trial 1 Recombinant Inactivated Trial 2 Recombinant Statistical Analysis The serologic data were related as powers of 2; thus, the base 2 logarithm titers were analyzed. Titers reported as <10 were recoded as 5 for analysis. Geometric mean titers (GMTs) were calculated. The transformed data and the difference between the log baseline titer and the 7- and 14-day postvaccination log titers (P =.09). By 14 days postvaccination, however, the difference in titers between horses vaccinated with the recombinant (GMT = 1,400) and the inactivated (GMT = 545) vaccine approached significance (P =.06) in favor of the recombinant vaccine. The magnitude of the change of log titer from day of vaccination to 14 days postvaccination was significantly higher for horses that received the recombinant vaccine than for horses vaccinated with the inactivated product (P =.02). Trial 2 (Solano County, California) The distribution of initial WNV serum antibody titers is presented in Table 4. The starting GMT for the horses from the non WNV By 14 days, the difference in titers in Trial 1 horses vaccinated with the recombinant vaccine approached significance in favor of the recombinant vaccine. were analyzed using one-way analysis of variance. Statistical significance was based on twotailed tests of the null hypothesis with P.05. RESULTS Serum Neutralization Antibody (IgG) Trial 1 (Blount County, Tennessee) The distribution of initial WNV serum antibody titers between the vaccination groups is tabulated in Table 2, and the results of the statistical analysis of the data are presented in Table 3. There was no significant difference (P >.10) between the vaccine groups for baseline GMT, although a wide range of titers was observed. All horses showed an anamnestic response within 7 days of vaccination, with no significant differences between the two groups endemic region was comparable to that of those in the endemic area (GMT = 20). By 16 days postvaccination, the GMT in this group of horses was 3,981. IgM Antibody Samples from all of the horses in Trial 1, at all time points, were negative when assayed for WNV-specific IgM (data not shown). DISCUSSION Recombinant and inactivated vaccines induced an anamnestic, humoral response in horses vaccinated previously with the inactivated WNV vaccine. Although the role of serumneutralizing antibodies in protecting horses from WNV disease has not been established, 254
5 the level of antibodies induced following revaccination was much higher than that of previous studies in which horses vaccinated with the recombinant vaccine were protected from WNV challenge. 1,11,12 Increases in GMT were observed as early as 7 days postvaccination; by 14 days, horses in the WNV endemic groups receiving the recombinant vaccine approached a significantly higher GMT than those revaccinated with the inactivated product. Statistical comparison of the data from the endemic versus nonendemic area was not made because of differences in primary vaccination schedule and sampling times. Not all of the horses in this study were seronegative for WNV antibody before vaccination. The effects of the previous vaccination can satisfactorily explain low levels of serum antibody in approximately half of the horses in Trial 1. The location of the herd used in this study was Blount County, Tennessee, for which no positive mosquitoes were reported during the time of the study, but six equine TABLE 3. Geometric Mean Antibody Titer, Range, and Difference in Log 2 Titer from Day 0 for Horses in Blount County, Tennessee (Trial 1) a Recombinant Inactivated Day Vaccine (n = 14) Vaccine (n = 13) P value 0 19 ( ) 26 ( ) > (80 2,560) 465 (40 1,280) > ,400 (320 5,120) 545 (40 2,560) (change) (change) a Horses were vaccinated on day 0 with a canarypox-based recombinant WNV vaccine or an inactivated WNV vaccine; all horses had been previously vaccinated with the inactivated WNV vaccine. some horses, it is unlikely that the horses had recent exposure to WNV, since no IgM antibody was detectable in any of the sera of horses from the WNV-endemic area. The presence of IgM antibody in acute-phase serum samples is generally regarded as evidence of recent exposure to live virus. 13,14 In one study, IgM antibody in convalescent serum samples persisted beyond 2 months after the onset of illness in more than 50% of the cases 14 ; however, in some horses, WNV-specific IgM may only be detectable in serum for a few days. In this The results of this study clearly demonstrate that vaccination of horses with a recombinant WNV vaccine following a primary course of killed vaccine elicits a relevant serologic response that is greater in magnitude than revaccination with the homologous, killed vaccine. and six avian cases of WNV had been detected in Although natural infection is a possible explanation in regard to the magnitude of the starting serum neutralization endpoints in study, primary response to recent natural infection was not considered to be a complicating factor, but the possibility that starting titers originated from both previous vaccination and 255
6 Veterinary Therapeutics Vol. 5, No. 4, Winter 2004 TABLE 4. Geometric Mean Antibody Titer, Range, and Difference in Log 2 Titer from Day 0 for Horses in Solano County, California (Trial 2) a Day Recombinant Vaccine (n = 11) 0 20 ( 10 1,280) 16 3,981 (1,280 10,240) 29 2,138 (320 5,120) 0 16 (change) (change) 6.55 a Horses were vaccinated on day 0 with a canarypoxbased recombinant WNV vaccine; all horses had been previously vaccinated with the inactivated WNV vaccine. a history of natural exposure cannot be ruled out. However, the response in WNV-endemic horses did not differ from that of horses from Solano County, California, an area in which no cases of WNV had been reported up to and including the study period. 9 Therefore, these horses were unlikely to have been subjected to recent exposure to the wild-type WNV. The kinetics of humoral antibody induction in all horses, regardless of which vaccine was used, supported a consistent and rapid response to vaccination. Thus, the anamnestic response to immunologic challenge by the complete complement of viral antigens is produced by both reintroduction of the inactivated vaccine and the presentation of immunodominant envelope protein genes in the recombinant canarypox-vector format. The results of this study clearly demonstrate that vaccination of horses with a recombinant WNV vaccine following a primary course of killed vaccine elicits a relevant serologic response that is greater in magnitude than revaccination with the homologous, killed vaccine. Further studies addressing the compatibility of different vaccine modalities will be of great value. This is the first study that addresses concerns regarding the ability of a recombinant WNV vaccine to elicit an anamnestic immune response to WNV in horses previously vaccinated with an inactivated vaccine. CONCLUSION Vaccination of horses with a canarypox-vectored recombinant vaccine expressing the prm and E genes of WNV, under field conditions, results in a marked anamnestic response in horses previously vaccinated with an inactivated WNV vaccine. ACKNOWLEDGMENTS We thank R. Bowen, DVM, PhD, for valuable discussions and his review of the manuscript and for performing the serum neutralization WNV serum antibody titrations. We also thank the Center for Equine Health at the University of California, Davis, for providing equine sera from the Solano County site. REFERENCES 1. Minke JM, Siger L, Karaca K, et al: Recombinant canarypoxvirus vaccine carrying the prm/e genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol 18(suppl): , Siger L, Bowen R, Karaca K, et al: Efficacy in horses of a single dose of an ALVAC recombinant West Nile Virus (WNV) vaccine, measured by protection to a natural challenge using WNV-infected mosquitoes. Am J Vet Res 65: , Plotkin SA, Cadoz M, Meignier B, et al: The safety and use of canarypox vectored vaccines. Dev Biol Stand 84: , Taylor J, Trimarchi C, Weinberg R, et al: Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9(3): , Kanesa-Thasan N, Smucny JJ, Hoke CH, et al: Safety and immunogenicity of NYCAC-JEV and ALVAC- JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19: , Franklin RP, Kinde H, Michele TJ, et al: Eastern equine encephalomyelitis virus infection in a horse from California. Emerg Infect Dis 8(3): ,
7 7. Wilkins PA, Del Piero F: West Nile virus: Lessons from the 21 st century. J Vet Emerg Crit Care 14(1):2 14, US Department of the Interior: U.S. Geological Survey: West Nile Virus Maps: Tennessee Veterinary. Available at html; accessed December 14, US Department of the Interior: U.S. Geological Survey: West Nile Virus Maps: California Veterinary. Available at veterinary.html; accessed December 14, Bunning ML, Bowen RA, Cropp CB, et al: Experimental infection of horses with West Nile Virus. Emerg Infect Dis 8(4): , Davis BS, Chang GJ, Cropp B, et al: West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75: , Chu H-J: West Nile Vaccine. US Patent No.: US 2003/ Issued May 15, Long MT, Ostlund EN, Porter MB, Crom RL: Equine West Nile Encephalitis: Epidemiological and clinical review for practitioners. Proc AAEP 48:1 6, Tardei G, Ruta S, Chitu V, et al: Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile virus infection. J Clin Microbiol 36(6): ,
Leonardo Siger, DVM, MS; Richard A. Bowen, DVM, PhD; Kemal Karaca, DVM, PhD; and Jules M. Minke, DVM, PhD MEDICINE INFECTIOUS DISEASES
Evaluation of the Efficacy Provided by a Recombinant Canarypox-Vectored Equine West Nile Virus Vaccine Against an Experimental West Nile Virus Intrathecal Challenge in Horses Leonardo Siger, DVM, MS; Richard
More informationAnalysis of Recombinant Canarypox Vectored West Nile Virus Vaccine Stability Post- Reconstitution
Analysis of Recombinant Canarypox Vectored West Nile Virus Vaccine Stability Post- Reconstitution Janice Coon, BS 1 Michael Johnston, BS 1 Jules Minke, DVM, PhD 2 Ray Pruett, MS 1 Stephanie Thompson, DVM
More informationc Merial Limited d Merial SAS Limited
L. Siger, R. Bowen, K. Karaca, M. Murray, S. Jagannatha, B. Echols, R. Nordgren, and J. M. Minke Evaluation of the Efficacy Provided by a Recombinant Canarypox-Vectored Equine West Nile Virus Vaccine against
More informationSEROLOGIC RESPONSE TO WEST NILE VIRUS VACCINATION IN THE GREATER ONE-HORNED RHINOCEROS (RHINOCEROS UNICORNIS)
Journal of Zoo and Wildlife Medicine 39(4): 537 541, 2008 Copyright 2008 by American Association of Zoo Veterinarians SEROLOGIC RESPONSE TO WEST NILE VIRUS VACCINATION IN THE GREATER ONE-HORNED RHINOCEROS
More informationSerologic Responses to Eastern and Western Equine Encephalomyelitis Vaccination in Previously Vaccinated Horses*
Serologic Responses to Eastern and Western Equine Encephalomyelitis Vaccination in Previously Vaccinated Horses* Bryan M. Waldridge, DVM, MS, DABVP, DACVIM a,d James G. W. Wenzel, DVM, PhD, DACT, DACVPM
More informationEffect of Recombinant Canine Distemper Vaccine on Antibody Titers in Previously Vaccinated Dogs*
L. J. Larson, T. L. Hageny, C. J. Haase, and R. D. Schultz Effect of Recombinant Canine Distemper Vaccine on Antibody Titers in Previously Vaccinated Dogs* L. J. Larson, DVM T. L. Hageny, BS C. J. Haase,
More informationJEAN-CHRISTOPHE AUDONNET
JEAN-CHRISTOPHE AUDONNET Recombinant Veterinary Vaccines Overview of Progress in the past 30 years and Future Trends Jean-Christophe AUDONNET DVM, Ph.D. Merial R&D OUTLINE OF THE TALK 01 02 ORIGIN AND
More informationResponse to Modified Live and Killed Multivalent Viral Vaccine in Regularly Vaccinated, Fresh Dairy Cows*
E. J. Dubovi, Y. T. Gröhn, M. A. Brunner, and J. A. Hertl Response to Modified Live and Killed Multivalent Viral Vaccine in Regularly Vaccinated, Fresh Dairy Cows* Edward J. Dubovi, PhD a Yrjo T. Gröhn,
More informationLong-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV)
Long-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV) Sutee Yoksan, M.D., Ph.D. Center for Vaccine Development, Mahidol University Joint
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationSEROLOGICAL DIAGNOSIS OF DENGUE INFECTIONS
ECDC training Workshop on laboratory diagnosis of dengue virus infections Berlin, 23 27 January 2012 SEROLOGICAL DIAGNOSIS OF DENGUE INFECTIONS Cristina Domingo Carrasco Robert Koch Institut FACILITIES
More informationEquine West Nile Encephalitis: The 2002 U.S. Epizootic. Eileen Ostlund, DVM, PhD Randy Crom, DVM Tim Cordes, DVM USDA / APHIS/ VS
Equine West Nile Encephalitis: The 2002 U.S. Epizootic Eileen Ostlund, DVM, PhD Randy Crom, DVM Tim Cordes, DVM USDA / APHIS/ VS 1 Acknowledgments Data on equine cases of West Nile virus (WNV) infection
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationAdverse Event GACVS. Global Advisory Committee on Vaccine Safety, 910 June 2005
Adverse Event The Committee considered the decision taken by the Government of Japan on 30 May 2005 to suspend routine vaccination with the mouse brainderived Japanese encephalitis (JE) vaccine currently
More informationMeasles and Measles Vaccine
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition
More informationVACCINATIONS FOR FOALS
VACCINATIONS FOR FOALS **ALL VACCINATION PROGRAMS SHOULD BE DEVELOPED IN CONSULTATION WITH A LICENSED VETERINARIAN** The two categories below reflect differences in the foal s susceptibility to disease
More information9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
More informationWest Nile Virus. By Frank Riusech
West Nile Virus By Frank Riusech Disease Etiology: West Nile virus(wnv), genus, flavivirus is positive- stranded RNA arbovirus (arthropod- borne), belonging to the Flaviviridae family. Included in this
More informationRelevance of Detection of Immunoglobulin M Antibody Response in Birds Used for Arbovirus Surveillance
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1986, p. 770-774 0095-1137/86/1770-05$02.00/0 Copyright C) 1986, American Society for Microbiology Vol. 24, No. 5 Relevance of Detection of Immunoglobulin M Antibody
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Proteq West Nile suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1
More informationArbovirus Infections and the animal reservoir
Arbovirus Infections and the animal reservoir Arboviruses ecologically based designation >100 cause disease in humans and animals changes in taxonomy viral morphology, structure, and function distributed
More informationcertificate, the horses will be returned or destroyed by AQSIQ. Article 2 Article 3 Article 4 Article 5
PROTOCOL BETWEEN THE FEDERAL AGENCY FOR THE SAFETY OF FOOD CHAIN OF THE KINGDOM OF BELGIUM AND THE GENERAL ADMINISTRATION OF QUALITY SUPERVISION, INSPECTION AND QUARANTINE OF THE PEOPLE S REPUBLIC OF CHINA
More informationsalmonella abortus-equi
21 266 21 5 28 salmonella abortus-equi 5 ( ) ( ) ( ) ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) (a) (b) OIE ANIMAL HEALTH REQUIREMENTS FOR HORSES TO BE EXPORTED TO JAPAN FROM NEW ZEALAND This document defines the animal
More informationJapanese Encephalitis: Prevention Through Vaccination. Jaime A. Santos
Japanese Encephalitis: Prevention Through Vaccination Jaime A. Santos Outline Introduction: Epidemiology, Disease and Sequelae Prevention: Role of Vaccination Vaccines against JE; SP Chimeric Vaccine Conclusions
More informationLaboratory Testing for West Nile Virus Infections Testing Human & Non-Human Tissues
Laboratory Testing for West Nile Virus Infections Testing Human & Non-Human Tissues Robert S Lanciotti Chief; Diagnostic & Reference Laboratory Arbovirus Diseases Branch Fort Collins, Colorado Presentation
More informationMINISTERIO DE MEDIO AMBIENTE Y MEDIO RURAL Y MARINO WEST NILE CURRENT SITUATION, NATIONAL SURVEILLANCE PROGRAM AND FUTURE OF THE DISEASE IN SPAIN
WEST NILE CURRENT SITUATION, NATIONAL SURVEILLANCE PROGRAM AND FUTURE OF THE DISEASE IN SPAIN WNV NATIONAL SURVEILLANCE PROGRAM IN SPAIN (I) Surveillance ( EVITAR NET framework) since 2001 (Doñana, Delta
More informationCross-Reactivity to Field Isolates of Canine Influenza Virus by a Killed Canine Influenza Virus (H3N8, Iowa05) Vaccine
Cross-Reactivity to Field Isolates of Canine Influenza Virus by a Killed Canine Influenza Virus (H3N8, Iowa05) Vaccine Nancee Oien, B.S., M.S. a Sally Mattern, B.S a Jaime Brozowski, B.S., M.S. b Janet
More informationClinical Utility of Commercial Enzyme Immunoassays during the Inaugural Season of West Nile Virus Activity, Alberta, Canada
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2005, p. 4691 4695 Vol. 43, No. 9 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.9.4691 4695.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationRespiratory Syncytial Virus: Implications for Parenteral
INFECTION AND IMMUNITY, July 1982, p. 160-165 0019-9567/82/070160-06$02.00/0 Vol. 37, No. 1 Comparison of Enzyme-Linked Immunosorbent Assay and Neutralization Techniques for Measurement of Antibody to
More informationMosquitoborne Viral Diseases
Mosquitoborne Viral Diseases Originally prepared by Tom J. Sidwa, D.V.M, M.P.H State Public Health Veterinarian Zoonosis Control Branch Manager Texas Department of State Health Services 1 AGENT Viruses
More informationFlavivirus Vaccines Japanese Encephalitis and Dengue
Flavivirus Vaccines Japanese Encephalitis and Dengue 14 th Advanced Vaccinology Course Veyrier du Lac, France May 16, 2012 Harold S. Margolis, MD Dengue Branch Centers for Disease Control and Prevention
More information2009 H1N1 Influenza ( Swine Flu ) Hemagglutinin ELISA kit
2009 H1N1 Influenza ( Swine Flu ) Hemagglutinin ELISA kit Catalog Number : SEK001 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as
More informationClass-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection
Microbiol. Immunol., 39(10), 795-799, 1995 Class-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection Takashi Kawana*,1,
More informationDIAGNOSTICS ALGORITHMS IN DENGUE INFECTIONS
ECDC training Workshop on laboratory diagnosis of dengue virus infections Berlin, 23 27 January 2012 DIAGNOSTICS ALGORITHMS IN DENGUE INFECTIONS Cristina Domingo Carrasco Robert Koch Institut KINETICS
More informationIdentification of Microbes Lecture: 12
Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected
More informationIncidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California
Vet. Res. 38 (2007) 109 116 109 c INRA, EDP Sciences, 2007 DOI: 10.1051/vetres:2006045 Short Note Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California
More informationDevelopment and Persistence of West Nile Virus-Specific Immunoglobulin M (IgM), IgA, and IgG in Viremic Blood Donors
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2005, p. 4316 4320 Vol. 43, No. 9 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.9.4316 4320.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationVaccination Guidelines - AAEP
Vaccination Guidelines - AAEP 12/04/12 13:53 Vaccination Guidelines These guidelines are intended to be a reference used by veterinarians utilizing vaccines in their respective practices. They are neither
More informationThe Science of Protected
The Science of Protected Merck Animal Health Vaccine Collection Our aim is to help horses live long, healthy and productive lives. Merck Animal Health OVER 70 YEARS of INNOVATIVE ANIMAL HEALTH SOLUTIONS
More informationDengue Virus IgM Elisa kit
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationM I C R O B I O L O G Y
ninth edition TORTORA FUNKE CASE M I C R O B I O L O G Y a n i n t r o d u c t i o n 18 Practical Applications of Immunology PowerPoint Lecture Slide Presentation prepared by Christine L. Case Vaccine
More informationHIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)
HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual) BACKGROUND Human Immunodeficiency Virus ( HIV ) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to
More informationCouncil of State and Territorial Epidemiologists Position Statement
04-ID-01 Committee: Title: Infectious Disease Revision of the National Surveillance Case Definition of Diseases Caused by Neurotropic Domestic Arboviruses, Including the Addition to the NNDSS of Non-Neuroinvasive
More informationEquine viral vaccines: the past, present and future
Equine viral vaccines: the past, present and future Jules Minke, Jean-Christophe Audonnet, Laurent Fischer To cite this version: Jules Minke, Jean-Christophe Audonnet, Laurent Fischer. Equine viral vaccines:
More informationFeline Panleukopenia Vaccine
Feline Panleukopenia Vaccine Modified Live Virus For use in cats only P FPO 2D PRODUCT DESCRIPTION: Felocell P is for vaccination of healthy cats as an aid in preventing feline panleukopenia caused by
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationLongitudinal Studies of Neutralizing Antibody Responses to Rotavirus in Stools and Sera of Children following Severe Rotavirus Gastroenteritis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 1998, p. 897 901 Vol. 5, No. 6 1071-412X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Longitudinal Studies of
More informationInfluenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set
Influenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set Catalog Number : SEK001 To achieve the best assay results, this manual must be read carefully before using this product and the assay
More informationUse of Immunoglobulin M Cross-Reactions in Differential Diagnosis of Human Flaviviral Encephalitis Infections in the United States
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 2002, p. 544 549 Vol. 9, No. 3 1071-412X/02/$04.00 0 DOI: 10.1128/CDLI.9.3.544 549.2002 Use of Immunoglobulin M Cross-Reactions in Differential Diagnosis
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: West Nile Virus Illness Revised March 2017 West Nile Virus Illness
More informationESCMID Online Lecture Library. by author
Update and Prospects for CMV Vaccine Robert Pass University of Alabama at Birmingham ESCMID Postgraduate Course Centro Universitario Residenziale di Bertinoro 29 Sept 29 3 Oct 2013 Disclosures: Partial
More informationPreclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against West Nile Virus
Viruses 2013, 5, 3048-3070; doi:10.3390/v5123048 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Preclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against
More informationEvaluation of the West Nile Surveillance System for the State of Kansas
Evaluation of the West Nile Surveillance System for the State of Kansas MPH Capstone Experience Conducted at Kansas Department of Health and Environment Presented By Katie Flock, DVM Public Health Surveillance
More informationInfluenza A H1N1 HA ELISA Pair Set
Influenza A H1N1 HA ELISA Pair Set for H1N1 ( A/Puerto Rico/8/1934 ) HA Catalog Number : SEK11684 To achieve the best assay results, this manual must be read carefully before using this product and the
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationPCV2 and Mycoplasma Vaccine Comparison in a Midwest Commercial Swine Herd
PCV2 and Mycoplasma Vaccine Comparison in a Midwest Commercial Swine Herd STUDY BULLETIN Merck Animal Health Swine Technical Services Introduction In this report, a swine veterinarian investigated the
More informationEffect of Complement and Viral Filtration on the
APPLIED MICROBIOLOGY, JUlY 1968, p. 1076-1080 Copyright @ 1968 American Society for Microbiology Vol. 16, No. 7 Printed in U.S.A. Effect of Complement and Viral Filtration on the Neutralization of Respiratory
More informationHuman HBcAb IgM ELISA kit
Human HBcAb IgM ELISA kit Catalog number: NR-R10163 (96 wells) The kit is designed to qualitatively detect HBcAb IgM in human serum or plasma. FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PURPOSES
More informationAAEP Vaccination Guidelines
AAEP Vaccination Guidelines Introduction These guidelines are intended to be a reference for veterinarians who utilize vaccines in their respective practices. They are neither regulations nor directives
More informationHuman Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set Catalog Number : SEK11695 To achieve the best assay results, this manual must be read carefully before using this product
More informationSPECIFIC ANTIINFECTIOUS IMMUNITY. colostral immunity. administration of antibodies VIRULENT VACCINE INACTIVATED VACCINE
INDUCTION OF IMMUNITY AGAINST INFECTION SPECIFIC ANTIINFECTIOUS IMMUNITY active passive S AND VACCINATION infection vaccination colostral immunity administration of antibodies VIRULENT MODIFIED LIVE INACTIVATED
More informationReview of the evidence: Vaccine immunogenicity, effec7veness, and impact
Review of the evidence: Vaccine immunogenicity, effec7veness, and impact Susan Hills MBBS, MTH Division of Vector- Borne Diseases Centers for Disease Control and Preven7on, Colorado, USA Outline q Inactivated
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationFELINE INFECTIOUS D ISE A SE S
FELINE INFECTIOUS D ISE A SE S Fred W. Scott, DVM, PhD Cornell Feline Health Center College of Veterinary Medicine Cornell University Ithaca, NY 1485 607-25-414 Fax: 607-25-419 e-mail: fws26cornell.edu
More informationArbovirus Reports 2015
Arbovirus Reports Arboviruses (Arthropod-borne) are a group of viral infections transmitted by the bite of arthropods, most commonly mosquitoes. Some of these infections are endemic; others may be imported
More informationDengue: The next vaccine preventable disease? Prof John McBride James Cook University
Dengue: The next vaccine preventable disease? Prof John McBride James Cook University Dengue viruses A flavivirus ~11kb genome, ~50nm diameter, lipid envelope. Gene order 5 C-prM-E-NS1 Four serotypes (1-4)
More informationE. Histolytica IgG (Amebiasis)
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationCase Study: West Nile Virus -Taking an Integrated National Public Health Approach to an Emerging Infectious Disease in Canada
2008/SOM3/HWG/WKSP/003 Case Study: West Nile Virus -Taking an Integrated National Public Health Approach to an Emerging Infectious Disease in Canada Submitted by: Canada Health Working Group Policy Dialogue
More informationprovided the original work is prope
NAOSITE: Nagasaki University's Ac Title Author(s) Persistence of Neutralizing Antibod Years from Infection in Nagasaki Ngwe Tun, Mya Myat; Muta, Yoshihito Citation BioResearch Open Access, 5(1), pp.1 Issue
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More informationCurrent Status of Dengue Diagnosis at the Center for Disease Control, Taiwan
Current Status of Dengue Diagnosis at the Center for Disease Control, Taiwan Pei-Yun Shu, Shu-Fen Chang, Yi-Yun Yueh, Ling Chow, Li-Jung Chien, Yu-Chung Kuo, Chien-Lin Su, Tsai-Ling Liao, Ting-Hsiang Lin
More informationAppendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)
Section A: Case Definitions Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005) The current Case Definitions were drafted with available information at the time of writing. Case Definitions
More informationKyoung-Jin Yoon 1, Bruce H. Janke, Rick W. Swalla, Gene Erickson
J Vet Diagn Invest 16:197 21 (24) Comparison of a commercial H1N1 enzyme-linked immunosorbent assay and hemagglutination inhibition test in detecting serum antibody against swine influenza viruses Kyoung-Jin
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ProteqFlu-Te Suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose contains:
More informationFlaviviruses New Challenges, New Vaccines
Flaviviruses New Challenges, New Vaccines Christian W. Mandl Institute of Virology Medical University of Vienna, AUSTRIA Family Flaviviridae Genus Hepacivirus Genus Pestivirus Genus Flavivirus (>70 members)
More informationWest Nile virus and other arboviral activity -- United States, 2013 Provisional data reported to ArboNET Tuesday, July 23, 2013
West Nile virus and other arboviral activity -- United States, 2013 Provisional data reported to ArboNET Tuesday, This update from the CDC Arboviral Diseases Branch includes provisional data reported to
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ProteqFlu suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 1 ml contains:
More informationFirst Probable West Nile Virus Case in the Simcoe-Muskoka Area
Dr. Charles Gardner, Medical Officer of Health Dr. Colin Lee, Associate Medical Officer of Health Dr. Lisa Simon, Associate Medical Officer of Health First Probable West Nile Virus Case in the Simcoe-Muskoka
More informationLongevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines
247 Appendix 31 Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines S. J Cox and P. V. Barnett Institute for Animal Health, Pirbright
More informationHuman Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set Catalog Number : SEK11233 To achieve the best assay results, this manual must be read carefully before using this product
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax Rabies suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationAppendix 72 Using NSP ELISA (Chekit-FMD-3ABC Bommeli-Intervet) as a Tool for FMDV Serosurveillance in Bulgaria Abstract: Introduction
Appendix 72 Using NSP ELISA (Chekit-FMD-3ABC Bommeli-Intervet) as a Tool for FMDV Serosurveillance in Bulgaria Georgi Georgiev*¹, Emiliya Veleva¹, Liliyana Polihronova¹ and Alessandro Rossi² 1 National
More informationDengue and Zika vaccine development
Dengue and Zika vaccine development Carolyn E. Clark, PhD, MPH Scientist, Infection Control and Environmental Health Norwegian Institute of Public Health Kurs i import- og reisemedisin for helsepersonell
More informationMaterial and methods. Challenge The pigs were challenged at 16 weeks of age when the challenge control pigs became antibody negative by the
Evaluation of the efficacy of Mycoplasma hyopneumoniae bacterin following immunization of young pigs in the presence of varying levels of maternal antibodies H. Jayappa * MVSc, PhD, R. Davis BS, V. Rapp-Gabrielson
More informationEQUINE DISEASES AND GUIDELINES
EQUINE DISEASES AND vaccination GUIDELINES CORE AND RISK VACCINATION GUIDELINES FOR ADULT HORSES ALL VACCINATION PROGRAMS SHOULD BE DEVELOPED IN CONSULTATION WITH A LICENSED VETERINARIAN The American Association
More informationTG4010. Public Information
TG4010 Public Information 11 May 2017 Public Information 11 May 2017 Page 2 /7 ABBREVIATIONS DNA Deoxyribonucleic acid GMO Genetically modified organism IL2 Interleukin-2 IM Intramuscular IT Intratumoral
More informationReceived 23 August 2007/Returned for modification 18 September 2007/Accepted 5 November 2007
CLINICAL AND VACCINE IMMUNOLOGY, Jan. 2008, p. 88 94 Vol. 15, No. 1 1556-6811/08/$08.00 0 doi:10.1128/cvi.00347-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Utilization of
More informationArbovirus Surveillance in Massachusetts 2016 Massachusetts Department of Public Health (MDPH) Arbovirus Surveillance Program
INTRODUCTION Arbovirus Surveillance in Massachusetts 2016 Massachusetts Department of Public Health (MDPH) Arbovirus Surveillance Program There are two mosquito-borne diseases of concern for transmission
More informationEQUINE DISEASES AND VACCINES
W 659 EQUINE DISEASES AND VACCINES Jennie L. Ivey, PhD, PAS, Assistant Professor Lew Strickland, DVM, MS, DACT, Assistant Professor Taylor Case, Animal Science Independent Study Department of Animal Science
More informationWest Nile Virus. Family: Flaviviridae
West Nile Virus 1 Family: Flaviviridae West Nile Virus Genus: Flavivirus Japanese Encephalitis Antigenic Complex Complex Includes: Alfuy, Cacipacore, Japanese encephalitis, koutango, Kunjin, Murray Valley
More informationWest Nile Virus. By Chimnonso Onuoha
West Nile Virus By Chimnonso Onuoha Family: Flaviviridae Genus: Flavivirus Etiologic agent- Japanese encephalitis Antigenic Complex Etiological Agent and Characteristics WNV is an arbovirus in the family
More informationDetection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity
Borgis New Med 2015; 19(4): 147-155 DOI: 10.5604/14270994.1191796 Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity *Mónika Rózsa 1, István Jankovics
More informationNEW VACCINES FOR PATHOGENS INFECTING ANIMALS AND HUMANS: ONE HEALTH. Thomas P Monath MD
NEW VACCINES FOR PATHOGENS INFECTING ANIMALS AND HUMANS: ONE HEALTH Thomas P Monath MD What is the One Health Initiative? Movement to forge interdisciplinary collaboration between medical, veterinary,
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationIt IS a Small World After All: The Public Health Impact and Immunologic Assessment of a Disneyland Measles Case in El Paso County, Colorado
It IS a Small World After All: The Public Health Impact and Immunologic Assessment of a Disneyland Measles Case in El Paso County, Colorado Panel: Robyn Espy, M.P.H, Marigny Klaber, M.Sc., Shannon Rowe,
More informationApproximately 4 million persons receive blood
TRANSFUSION COMPLICATIONS West Nile virus infection transmitted by blood transfusion Theresa Harrington, Matthew J. Kuehnert, Hany Kamel, Robert S. Lanciotti, Sheryl Hand, Mary Currier, Mary E. Chamberland,
More informationCHAPTER 4 IMMUNOLOGICAL TECHNIQUES
CHAPTER 4 IMMUNOLOGICAL TECHNIQUES Nitroblue Tetrazolium Chloride (NBT) Reduction test NBT reduction test was evaluated by employing the method described by Hudson and Hay,1989 based upon principle that
More informationJapanese Encephalitis IgM ELISA
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland Hills, California 91367 USA Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationTHE CYTOPATHOGENIC ACTION OF BLUETONGUE VIRUS ON TISSUE CULTURES AND ITS APPLICATION TO THE DETECTION OF ANTIBODIES IN THE SERUM OF SHEEP.
Onderstepoort Journal of Veterinary Research, Volume 27, Number 2, October, 1956. The Government Printer. THE CYTOPATHOGENIC ACTION OF BLUETONGUE VIRUS ON TISSUE CULTURES AND ITS APPLICATION TO THE DETECTION
More informationEquine Infectious Anemia
Equine Infectious Anemia CJ Issel, DVM, PhD University of Kentucky Gluck Equine Research Center Typical Clinical Course of EIAV Infections Acute Chronic Inapparent 42 10 9 10 8 41 200 Viral RNA log 10
More information